

MAR 8 1 2002

COPY OF PAPERS
ORIGINALLY FILED

Pocket N . 13761-0739

* a NF 8/11/02

Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):

[X] Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

[] Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner _____ at Facsimile No. _____ at _____ a.m./p.m.

Dated: February 13, 2002

Name of Person Certifying: _____

Printed Name: LAER BARRETT

Barrett

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lenz et al.

Assignee: University of Southern California

Filing Date: 11/15/00

Examiner: Zitomer, S.

Serial No.: 09/715,764

Group Art Unit: 1655

Title: **GENOMIC POLYMORPHISM FOR PREDICTING THERAPEUTIC RESPONSE**

RECEIVED
MAR 07 2002
OFFICE OF PETITIONS
DEPUTY AC PATENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

**AMENDMENT AND RESPONSE TO OFFICE ACTION DATED
AUGUST 1, 2001**

In response to the Office Action, dated August 1, 2001, in the above-identified patent application, Applicants respectfully request reconsideration of the application in view of the following Amendments and Remarks. This reply is not timely filed. A petition to revive the application under 37 C.F.R. § 1.137(b) accompanies this response.

I. CLAIM AMENDMENTS

Please cancel claims 1-34 without prejudice to pursuing the subject matter of these claims in a subsequent application. Please add new claims 35-60 as follows:

- 1 35. A method for the treatment of a cancer in a subject, the method comprising:
- 2 (a) determining a genomic polymorphism in the subject with said cancer;
- 3 (b) selecting a chemotherapeutic drug to administer to said subject to treat said cancer
- 4 depending on the type of genomic polymorphism determined in step (a); and
- 5 (c) administering said chemotherapeutic drug to said subject,